Sino Biopharmaceutical Beheer

Beheer criteriumcontroles 1/4

De CEO Sino Biopharmaceutical is Eric S. Y. Tse, benoemd in Jul2022, heeft een ambtstermijn van 2.33 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 49.69M, bestaande uit 45.4% salaris en 54.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 22.27% van de aandelen van het bedrijf, ter waarde HK$ 13.18B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 9.5 jaar.

Belangrijke informatie

Eric S. Y. Tse

Algemeen directeur

CN¥49.7m

Totale compensatie

Percentage CEO-salaris	45.4%
Dienstverband CEO	2.3yrs
Eigendom CEO	22.3%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	9.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Eric S. Y. Tse's beloning veranderd ten opzichte van Sino Biopharmaceutical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥50m	CN¥23m	CN¥2b
Jun 30 2023	n/a	n/a	CN¥1b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

Compensatie versus markt: De totale vergoeding ($USD 6.87M ) Eric S. Y. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 887.93K ).

Compensatie versus inkomsten: De vergoeding van Eric S. Y. is het afgelopen jaar met meer dan 20% gestegen.

CEO

Eric S. Y. Tse (28 yo)

2.3yrs

Tenure

CN¥49,691,000

Compensatie

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Y. Y. Tse	Executive Chairwoman of the Board	9.4yrs	CN¥49.69m	0.033% HK$ 19.5m
Eric S. Y. Tse	CEO & Executive Director	2.3yrs	CN¥49.69m	22.27% HK$ 13.2b
Ping Tse	Founder & Senior Executive Vice Chairman	4.3yrs	CN¥49.53m	9.11% HK$ 5.4b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.6yrs	CN¥43.13m	16.31% HK$ 9.6b
Zhoushan Tian	Executive Director	no data	CN¥1.91m	geen gegevens
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.96% HK$ 1.2b
Chun Ling Li	Chief Financial Officer	1.8yrs	geen gegevens	geen gegevens
Song Jin	Vice President of Public Affairs	no data	geen gegevens	geen gegevens
Sean Chen	Chief Strategy Officer	1.8yrs	geen gegevens	geen gegevens
Chau Ling Yu	Assistant VP & Financial Controller	no data	geen gegevens	geen gegevens
Oi Nin Chan	Company Secretary	9.3yrs	geen gegevens	geen gegevens
Toogood Ben	CEO of invoX & Head of Globalization	1.8yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1177 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Y. Y. Tse	Executive Chairwoman of the Board	9.4yrs	CN¥49.69m	0.033% HK$ 19.5m
Eric S. Y. Tse	CEO & Executive Director	5.1yrs	CN¥49.69m	22.27% HK$ 13.2b
Ping Tse	Founder & Senior Executive Vice Chairman	4.3yrs	CN¥49.53m	9.11% HK$ 5.4b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.6yrs	CN¥43.13m	16.31% HK$ 9.6b
Zhoushan Tian	Executive Director	9.6yrs	CN¥1.91m	geen gegevens
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.96% HK$ 1.2b
Zhengfei Lu	Independent Non-Executive Director	19yrs	CN¥376.00k	geen gegevens
Dakui Li	Independent Non-Executive Director	20.2yrs	CN¥376.00k	geen gegevens
Lu Fu Zhang	Independent Non-Executive Director	9.6yrs	CN¥376.00k	geen gegevens
Hong Lu	Independent Non-Executive Director	9.6yrs	CN¥342.00k	geen gegevens
Kwok Tung Li	Independent Non-Executive Director	3.9yrs	CN¥376.00k	0.00039% HK$ 230.8k

9.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1177 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

Sino Biopharmaceutical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Key Executive recently sold HK$51m worth of stock

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Key Executive recently bought HK$34m worth of stock

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Recent updates

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold HK$51m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022)

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Upcoming dividend of HK$0.06 per share

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021)

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Upcoming dividend of HK$0.04 per share

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"